Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation

Clin Lab Med. 2019 Mar;39(1):61-72. doi: 10.1016/j.cll.2018.10.005. Epub 2018 Dec 18.

Abstract

Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.

Keywords: Biomarkers; Graft versus host disease; Hematopoietic stem cell transplantation; Proteomics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / blood
  • Graft vs Host Disease / diagnosis*
  • Graft vs Host Disease / immunology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hepatic Veno-Occlusive Disease / complications*
  • Hepatic Veno-Occlusive Disease / diagnosis
  • Lung Diseases / complications*
  • Lung Diseases / diagnosis
  • Prognosis
  • Treatment Outcome

Substances

  • Biomarkers